Neurocrine Biosciences (NBIX) News
NASDAQ: NBIXHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
150.57-6.02 (-3.84%)
At close: Nov 20, 4:00 PM ET · Delayed 15 min
NBIX news summary
We found 50 recent headlines mentioning Neurocrine Biosciences (NBIX): 3 in the past week and 30 in the past 30 days, most often from Nasdaq, Seeking Alpha, PR Newswire. For price context, NBIX is down 3.84% at $150.57. The most recent story, "Neurocrine Biosciences (NBIX) is a Top-Ranked Momentum Stock: Should You Buy?", was published by Nasdaq on Nov 20, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Neurocrine Biosciences headlines
- Neurocrine Biosciences (NBIX) is a Top-Ranked Momentum Stock: Should You Buy?Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.Nasdaq
- Neurocrine Biosciences, Inc. (NBIX) Presents at Jefferies Global Healthcare Conference 2026 TranscriptSeeking Alpha
- Why Neurocrine Biosciences (NBIX) is a Top Growth Stock for the Long-TermThe Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.Nasdaq
- NBIX or GRDN: Which Is the Better Value Stock Right Now?NBIX vs. GRDN: Which Stock Is the Better Value Option?NasdaqNBIX, GRDN
- Looking for a Growth Stock? 3 Reasons Why Neurocrine (NBIX) is a Solid ChoiceNeurocrine (NBIX) could produce exceptional returns because of its solid growth attributes.Nasdaq
- All You Need to Know About Neurocrine (NBIX) Rating Upgrade to BuyNeurocrine (NBIX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.Nasdaq
- NBIX vs. GRDN: Which Stock Is the Better Value Option?NBIX vs. GRDN: Which Stock Is the Better Value Option?NasdaqNBIX, GRDN
- Wall Street Analysts See a 25.53% Upside in Neurocrine (NBIX): Can the Stock Really Move This High?The average of price targets set by Wall Street analysts indicates a potential upside of 25.5% in Neurocrine (NBIX). While the effectiveness of this highly sought-after metric is questionable, the…Nasdaq
- Neurocrine Biosciences: Breaking Down A Solid QuarterSeeking Alpha
- Neurocrine Biosciences: 3 Growth Drivers And An Attractive ValuationSeeking Alpha
- Neurocrine Biosciences: Up 15% After Q3, And The Research Engine Is Still Almost FreeSeeking Alpha
- Neurocrine Biosciences, Inc. 2026 Q3 - Results - Earnings Call PresentationSeeking Alpha
- Neurocrine Biosciences to Spotlight Its Scientific Journey and Growing Neuropsychiatry Pipeline at 2026 NEI Fall CongressSAN DIEGO, Nov. 3, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its participation in the 2026 Neuroscience Education Institute (NEI) Fall Congress, taking place…PR Newswire
- Why is Neurocrine Biosciences stock surging today?Investing.com
- Healthcare Stocks Move Higher: SIBN Rallies 18%, NBIX Gains 16%, RMTI Climbs 16%, PTCT Up 13%(RTTNews) - Healthcare stocks moved higher following quarterly earnings reports, acquisition news and capital allocation updates. SI-BONE and Neurocrine Biosciences advanced after reporting…NasdaqNBIX, PTCT, RMTI, SIBN
- NBIX Beats on Q3 Earnings & Sales, Raises '26 Ingrezza Sales ViewNeurocrine Biosciences beats Q3 earnings and revenue estimates as strong Ingrezza demand, Crenessity growth and higher 2026 sales guidance drive momentum.NasdaqNBIX, TGTX, AMRX
- Neurocrine (NBIX) Q3 2026 Earnings Call Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The MoNasdaq
- Neurocrine Biosciences Q3 Earnings Call Highlights3 Biotech Stocks to Watch: Iovance, Neurocrine & VikingNeurocrine Biosciences (NASDAQ:NBIX) reported record third-quarter net product sales exceeding $1.1 billion and record operating profitability,…Nasdaq
- Neurocrine Biosciences, Inc. (NBIX) Q3 2026 Earnings Call TranscriptSeeking Alpha
- Neurocrine Biosciences (NBIX) Q3 Earnings and Revenues Top EstimatesNeurocrine (NBIX) delivered earnings and revenue surprises of +29.53% and +8.12%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?NasdaqNBIX, ECOR
- Neurocrine (NBIX) Reports Q3 Earnings: What Key Metrics Have to SayAlthough the revenue and EPS for Neurocrine (NBIX) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall…Nasdaq
- Neurocrine Biosciences Inc Reveals Drop In Q3 Income(RTTNews) - Neurocrine Biosciences Inc (NBIX) revealed earnings for third quarter that Drops, from the same period last yearNasdaq
- Neurocrine Biosciences Reports Third-Quarter 2026 Financial ResultsTotal Third-Quarter 2026 Revenue Grew 41% Year-Over-Year to $1.1 Billion INGREZZA® (valbenazine) 2026 Net Sales Guidance Raised to $2.9 to $2.925 Billion SAN DIEGO, Nov. 2, 2026 /PRNewswire/ --…PR Newswire
- Neurocrine Biosciences Non-GAAP EPS of $3.29 beats by $0.54, revenue of $1.12B beats by $80MSeeking Alpha
- Here's Why Neurocrine Biosciences (NBIX) is a Strong Value StockWhether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.Nasdaq
- Here's Why Neurocrine Biosciences (NBIX) is a Strong Growth StockWhether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.Nasdaq
- Amneal Pharmaceuticals (AMRX) Earnings Expected to Grow: Should You Buy?Amneal (AMRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.NasdaqAMRX, NBIX
- Neurocrine Sets Benchmark For Measuring Health Improvements In Tardive Dyskinesia Patients(RTTNews) - Neurocrine Biosciences (NBIX) presented new research that establishes a benchmark for what constitutes a meaningful improvement in overall health for people living with tardive…Nasdaq
- Neurocrine Biosciences (NBIX) Earnings Expected to Grow: Should You Buy?Neurocrine (NBIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.Nasdaq
- Where Will Neurocrine Biosciences Be in 5 Years?Key PointsIngrezza remains Neurocrine's biggest revenue driver, with sales growing 15%.NasdaqNBIX, TEVA, ET
- Neurocrine Biosciences Announces Publication in Orphanet Journal of Rare Diseases Advancing Understanding of Hyperphagia in Prader-Willi SyndromeExpert perspectives highlight the interaction of hypothalamic dysfunction, biological, behavioral, and environmental factors in shaping the challenges of hyperphagia in Prader-Willi syndrome for…PR Newswire
- Neurocrine Presents Real-World Data Mapping Evolving Impact Of Congenital Adrenal Hyperplasia(RTTNews) - Neurocrine Biosciences (NBIX) reported real-world data demonstrating how the clinical and day-to-day impact of classic congenital adrenal hyperplasia can vary among individuals and evolve…NasdaqNBIX, BRK.A
- Neurocrine Biosciences Presents Real-World Evidence Mapping the Lifelong, Evolving Impact of Classic Congenital Adrenal HyperplasiaDecades of real-world medical records highlight the diverse challenges of living with classic congenital adrenal hyperplasia and how needs evolve from childhood through adulthood Patient records…PR Newswire
- NBIX October 2027 Options Begin TradingInvestors in Neurocrine Biosciences, Inc. (Symbol: NBIX) saw new options become available today, for the October 2027 expiration. One of the key inputs that goes into the price an option buyer is…Nasdaq
- Why Neurocrine Biosciences (NBIX) is a Top Value Stock for the Long-TermWhether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.Nasdaq
- NBIX vs. SDZNY: Which Stock Should Value Investors Buy Now?NBIX vs. SDZNY: Which Stock Is the Better Value Option?Nasdaq
- Why Neurocrine Biosciences (NBIX) is a Top Growth Stock for the Long-TermWhether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.Nasdaq
- Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2026 Financial ResultsConference Call and Webcast Scheduled for Monday, November 2 SAN DIEGO, Oct. 12, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has scheduled its third…PR Newswire
- 4 CNS Drug Stocks Worth Watching This World Mental Health DayAXSM, NBIX, ALKS and ACAD are advancing CNS treatments for mental health disorders, with growing product sales, pipeline progress and new growth opportunities.NasdaqALKS, NBIX, ACAD, AXSM
- Neurocrine Biosciences Reappoints Eiry Roberts As CMO, Keswani Departs(RTTNews) - Neurocrine Biosciences, Inc. (NBIX) announced that Eiry W. Roberts will return as Chief Medical Officer, effective immediately, succeeding Sanjay Keswani, who will depart the company by…Nasdaq
- Neurocrine Maps AI, China and Pipeline Strategy as INGREZZA Faces 2029 Price Hit3 Biotech Stocks to Watch: Iovance, Neurocrine & VikingNeurocrine Biosciences (NASDAQ:NBIX) outlined its commercial growth priorities, pricing considerations and pipeline plans during a Morgan…Nasdaq
- Neurocrine Biosciences, Inc. (NBIX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeeking AlphaNBIX, MS
- Neurocrine Biosciences, Inc. (NBIX) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference TranscriptSeeking Alpha
- Neurocrine Biosciences, Inc. (NBIX) Presents at Wells Fargo 21st Annual Healthcare Conference TranscriptSeeking Alpha
- Neurocrine's Crenessity Gains Ground in CAH: How Far Can Sales Go?NBIX's Crenessity gains rapid traction in CAH, with sales soaring and low patient penetration leaving room for growth.NasdaqNBIX, VRTX
- Nxera Secures $10 Mln Milestone Pay As FDA Accepts Neurocrine's IND Of NBI-1117567 In Alzheimer(RTTNews) - Nxera Pharma Co., Ltd. (4565.T) announced on Wednesday that its partner Neurocrine Biosciences Inc. (NBIX) has received acceptance from the U.S. Food and Drug Administration (FDA) for its…Nasdaq
- NBIX vs. TEVA: Which Drugmaker Is the Better Investment?Neurocrine's strong Ingrezza growth, Crenessity momentum and expanding pipeline make it the stronger pick over Teva despite valuation risks.NasdaqTEVA, NBIX, RDY, LLY
- Neurocrine Biosciences: 'House Full Of Options'Seeking Alpha
- Neurocrine's Ingrezza Sales Keep Growing: Can the Momentum Last?NBIX's Ingrezza sales climb 17% in 1H 2026 as strong volume drives a higher full-year outlook, but pricing risks loom.NasdaqNBIX, TEVA, ACAD
- Can NBIX's Q2 Beat and Higher Ingrezza Guidance Drive More Growth?Neurocrine's Q2 beat and higher Ingrezza guidance highlight strong growth, but rising spending and execution risks could test its expanding portfolio.NasdaqNBIX, BMY, TEVA